Background
==========

The etiology of the inflammatory bowel diseases (IBD) has been extensively studied \[[@B1]\], however, the environmental determinants of disease pathogenesis are not fully understood \[[@B2],[@B3]\]. IBD is widely believed to be associated with industrialization of nations. This hypothesis is supported by the significant geographic variation in IBD with the highest incidence rate of IBD in North America and Europe \[[@B4]\]. Migrant studies have demonstrated that immigrants, and particularly their offspring, from low prevalent regions acquire a similar risk of IBD as the local population \[[@B5]\]. Furthermore, the incidence of IBD is steadily rising in several developing nations as they have become industrialized \[[@B6],[@B7]\]. Within a country the incidence of IBD has been proposed to be higher in urban versus rural areas \[[@B8],[@B9]\].

Although numerous studies have investigated the association between urban environment and IBD, findings remain inconsistent. An urban association has been considered as far back as 1963, when Acheson and Nefzger suggested a positive relationship between urban areas and ulcerative colitis (UC) \[[@B10]\]. Many observational studies have subsequently shown an increase in UC and Crohn\'s disease (CD) incidence in more densely populated areas \[[@B8],[@B11]-[@B15]\]. Numerous studies, however, have failed to find an association between urban exposure and IBD \[[@B4],[@B16]\], while others have shown an inverse association \[[@B17]\]. Establishing whether the risk of IBD is greater in urban environments is important because environmental exposures in urban societies are significantly different than those in rural areas. This information may direct research initiatives on specific environmental risk factors of IBD and establish distribution of IBD burden in society.

A systematic analysis of the association between living in an urban environment and IBD has yet to be conducted. Thus, we performed a systematic review and meta-analysis of all case--control and cohort studies that explored the association between residing in an urban region and IBD in order to determine whether the risk of CD and/or UC was increased in urban as compared to rural areas.

Methods
=======

Search strategy
---------------

We conducted a systematic literature search using a predetermined protocol and in accordance with the quality of reporting meta-analyses of observational studies (MOOSE) \[[@B18]\]. We searched two computer-stored databases, Medline (1950-present) and Embase (Excerpta Medica Database; 1980-present) for studies describing the association between urban environment and IBD as of October 2009. The search strategy for Medline and Embase was conducted based on three themes. The first theme, the outcome measure, combined the exploded version of Medical Subject Headings (MESH) "inflammatory bowel disease" or "Colitis, Ulcerative" or "Crohn Disease". The second theme, the exposure, combined the exploded version of MESH headings "urban population" or "urban health" or "rural population" or "rural health" or "geography". The third theme combined exploded versions of MESH headings "risk factors" or "risk assessment" or "epidemiology" or "demography". All the keywords were used to search the titles and abstracts. The search was not limited by language or human subjects to ensure capture of all appropriate papers. Abstracts from the American College of Gastroenterology for 2006, 2007, and 2008, and the American Gastroenterological Association for 2006 and 2007 were reviewed. The reference lists of relevant articles were also reviewed.

Selection criteria
------------------

Two reviewers (N.M. and I.S.) identified articles eligible for further review by performing an initial screen of identified abstracts and titles. Articles were eliminated in this initial screen if they were not observational or did not either investigate environmental risk factors for IBD in a case--control study or investigate epidemiology of IBD using incident cases. Studies that did not report original data and duplicated publications were also excluded. Full-text of the remaining articles were retrieved and systematically reviewed. Articles were considered for inclusion in the second screening if they reported a measure of association between urban environment and UC and/or CD. In both study designs, UC and CD were required to be reported separately for inclusion into the systematic review. Studies that did not report adequate information to calculate incidence rate ratio (IRR) or odds ratio (OR) with 95% confidence interval (CI) were excluded. Disagreement between reviewers was resolved by consensus with third party experts (DR and GK).

Data extraction
---------------

The outcome variable of interest was defined as the presence of UC and/or CD. The exposure variable of interest was residing in an urban versus rural environment. Urban and rural populations were not consistently defined across all studies. Several studies (n = 10 for UC; n = 11 for CD) did not define an urban and/or rural environment \[[@B12],[@B13],[@B16],[@B17],[@B19]-[@B31]\]. The studies that defined this exposure used definitions that varied and some papers stratified by multiple levels of exposure (e.g. urban, semi-urban, and rural) \[[@B24],[@B32]-[@B36]\]. A priori we identified studies that defined urban as a population greater than 10,000 \[[@B37],[@B38]\]. Secondary variables extracted from the manuscripts included: study design (i.e. case--control or cohort); country of origin; publication year; timing of exposure; source of controls for case--control studies; and information on key indicators of study quality, using MOOSE \[[@B18]\].

We extracted reported OR and IRR with 95% (CIs) or data enabling the calculation of these association measures. Both adjusted and unadjusted values were extracted; though, when available, the adjusted estimates were used.

Statistical analysis
--------------------

Meta-analyses were initially conducted by combining cohort and case--control studies using IRRs, defined as the incidence rate of IBD in urban versus rural populations. Given the low prevalence of IBD, the OR would approximate the IRR under the rare disease assumption. Case--control and cohort studies were then analyzed separately using different measures of association. The IRR was used as measure of association for cohort studies and OR was used for case--control studies. The Test of Heterogeneity was performed using a Q statistic (5% level) and random effects models were used because of the presence of heterogeneity between studies. Stratified analyses were performed to explore factors that may explain heterogeneity between studies. Publication year was a priori stratified into three year categories: 1962--1988; 1989--1998; and 1999--2009. Similarly, stratified analyses and meta-regression were performed based on study design (i.e. case--control or cohort study), region of publication, timing of exposure, and source of controls in case--control studies. Sensitivity analyses were performed to exclude studies that did not include a definition of urban/rural region. Further sensitivity analysis was conducted on studies that used \>10,000 people as a definition of urban environment \[[@B37],[@B38]\]. Papers that stratified by multiple levels of exposure (e.g. urban, semi-urban, and rural) were analyzed as urban versus rural. The possibility of publication bias was assessed using the Begg tests.

Results
=======

Literature search
-----------------

The search strategy retrieved 6940 unique citations: 2964 from Medline and 3976 from Embase. Of these, 6434 citations were excluded after the first screening based on titles and abstracts, leaving 506 articles for full-text review (Figure [1](#F1){ref-type="fig"}). The observed agreement between reviewers for eligibility of articles was 97%, corresponding to a kappa statistic of 0.77. Upon full text review of 506 articles, 466 were excluded (see Figure [1](#F1){ref-type="fig"} for rationale of exclusions), leaving 40 studies for final inclusion in the systematic review and meta-analysis. Of these 40 studies, 25 investigated the relationship between urban environment and UC and 30 investigated this relationship with CD. Included in our analysis were 7 case--control UC studies, 9 case--control CD studies, 18 cohort UC studies, and 21 cohort CD studies.
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Demographic and study quality characteristics
---------------------------------------------

Characteristics of the 18 cohort studies for UC are shown in Table [1](#T1){ref-type="table"}\[[@B19]-[@B21],[@B23],[@B24],[@B32]-[@B35],[@B39]-[@B45]\]. The reported incidence rate ranged from 0.97 to 15.6 per 100,000/year. A definition for urban and/or rural environment was provided for 13 cohort studies. Characteristics of the 7 selected case--control studies for UC are shown in Table [2](#T2){ref-type="table"}\[[@B8],[@B12],[@B17],[@B26]-[@B28],[@B46]\]. Two of the studies had definitions for urban and/or rural environment. Characteristics of the 21 selected cohort studies for CD are shown in Tables  [1](#T1){ref-type="table"}\[[@B14],[@B15],[@B22],[@B23],[@B25],[@B30],[@B31],[@B36],[@B39]-[@B43],[@B45],[@B47]-[@B52]\]. The reported incidence rate of CD ranged from 0.51 to 15.6 per 100,000/year. A definition for urban environment was reported in 16 studies. Characteristics of the nine selected case--control studies for CD are shown in Table [2](#T2){ref-type="table"}\[[@B8],[@B13],[@B16],[@B17],[@B27],[@B29],[@B46],[@B53]\]. The studies were based in North America, Australia, Asia and Europe. The association between urban environment and IBD was not the primary outcome of interest in any of the cohort or case--control studies.

###### 

Characteristics of cohort studies for ulcerative colitis and Crohn's disease studies

  **Study characteristics and demographics**   **Study Quality Characteristics**                                                                  
  -------------------------------------------- ----------------------------------- --------- ------ ------ ----- ----- ----- ----- -------------- -----
  *Ulcerative Colitis*                                                                                                                            
  Mate-Jimerez 1994 \[[@B39]\]                 Spain                               1981-88   111    3.16   Yes   Yes   Yes   Yes   At diagnosis   No
  Ekbom 1991 \[[@B40]\]                        Sweden                              1965-83   2509   10.5   Yes   Yes   Yes   No    At diagnosis   No
  Linden 1971 \[[@B19]\]                       Finland                             1967      223    4.76   No    N/A   No    No    At diagnosis   No
  Probert 1992 \[[@B32]\]                      UK                                  1972-80   192    5.33   Yes   Yes   Yes   No    At diagnosis   Yes
  Probert 1992 \[[@B32]\]                      UK                                  1981-89   211    7.29   Yes   Yes   Yes   No    At diagnosis   Yes
  Niv 1990 \[[@B33]\]                          Israel                              1967-86   43     2.33   Yes   No    Yes   No    At diagnosis   Yes
  Kildebo 1990 \[[@B22]\]                      Norway                              1983-86   179    13.2   Yes   Yes   No    No    At diagnosis   No
  Gheorghe 2004 \[[@B23]\]                     Romania                             2002-03   163    0.97   Yes   Yes   No    No    At diagnosis   No
  Sincic 2006 \[[@B41]\]                       Croatia                             2000-04   70     4.6    Yes   Yes   Yes   No    At diagnosis   No
  Tsianos 1994 \[[@B24]\]                      Greece                              1982-91   61     4.18   Yes   Yes   No    No    At diagnosis   Yes
  Ladas 2005 \[[@B34]\]                        Greece                              1990-94   56     10.6   Yes   Yes   Yes   Yes   At diagnosis   Yes
  Moller 1971 \[[@B20]\]                       Finland                             1956-67   505    1.07   Yes   Yes   No    No    At diagnosis   No
  Blanchard 2001 \[[@B42]\]                    Canada                              1987-96   1763   15.6   Yes   Yes   Yes   No    At diagnosis   No
  Green 2006 \[[@B15]\]                        Canada                              1990-01   N/A    13.5   No    N/A   Yes   No    At diagnosis   No
  Lakatos 2003 \[[@B43]\]                      Hungary                             1977-01   560    5.89   Yes   Yes   Yes   No    At diagnosis   No
  Manousos 1996 \[[@B44]\]                     Greece                              1990-94   117    8.9    Yes   Yes   Yes   No    At diagnosis   No
  Wigley 1962 \[[@B35]\]                       New Zealand                         N/A       132    N/A    Yes   No    Yes   Yes   At diagnosis   Yes
  Latour 1996 \[[@B45]\]                       Belgium                             1993-94   36     3.5    Yes   Yes   Yes   No    At diagnosis   No
  *Crohn's Disease*                                                                                                                               
  Kyle 1971 \[[@B47]\]                         UK                                  1955-69   166    1.98   Yes   Yes   Yes   No    At diagnosis   No
  Jayanthi 1992 \[[@B48]\]                     UK                                  1972-80   161    2.89   Yes   Yes   Yes   Yes   At diagnosis   No
  Jayanthi 1992 \[[@B48]\]                     UK                                  1981-89   233    4.48   Yes   Yes   Yes   Yes   At diagnosis   No
  Mate-Jimerez 1994 \[[@B39]\]                 Spain                               1981-88   57     1.61   Yes   Yes   Yes   Yes   At diagnosis   No
  Ekbom 1991 \[[@B40]\]                        Sweden                              1965-83   1469   6.09   Yes   Yes   Yes   No    At diagnosis   No
  Shivananda 1987 \[[@B36]\]                   Netherlands                         1979-83   54     3.90   Yes   Yes   Yes   No    At diagnosis   Yes
  Kildebo 1989 \[[@B22]\]                      Norway                              1983-86   82     5.85   Yes   Yes   No    No    At diagnosis   No
  Kyle 1992 \[[@B49]\]                         Scotland                            1955-88   856    5.65   Yes   Yes   Yes   No    At diagnosis   No
  Manousos 1996 \[[@B44]\]                     Greece                              1990-94   37     3.00   Yes   Yes   Yes   Yes   At diagnosis   No
  Gheorghe 2004 \[[@B23]\]                     Romania                             2002-03   85     0.51   Yes   Yes   No    No    At diagnosis   No
  Sincic 2006 \[[@B41]\]                       Croatia                             2000-04   100    6.50   Yes   Yes   Yes   No    At diagnosis   No
  Phavichitr 2003 \[[@B25]\]                   Australia                           1971-01   351    1.02   Yes   Yes   No    No    At diagnosis   No
  Moum 1996 \[[@B50]\]                         Norway                              1990-93   225    5.86   Yes   Yes   Yes   No    At diagnosis   No
  Blanchard 2001 \[[@B42]\]                    Canada                              1987-96   1765   15.6   Yes   Yes   Yes   No    At diagnosis   No
  Green 2006 \[[@B15]\]                        Canada                              1990-01   N/A    14.8   No    N/A   Yes   No    At diagnosis   No
  Lakatos 2003 \[[@B43]\]                      Hungary                             1977-01   212    2.23   Yes   Yes   Yes   No    At diagnosis   No
  Nyhlin 1986 \[[@B51]\]                       Sweden                              1974-81   253    4.90   Yes   Yes   Yes   No    At diagnosis   No
  Ruiz Ochoa 1984 \[[@B30]\]                   Spain                               1976-83   152    0.80   Yes   Yes   No    No    At diagnosis   No
  Sedlack 1980 \[[@B31]\]                      USA                                 1935-75   103    4.20   Yes   No    No    No    At diagnosis   No
  Brandes 1983 \[[@B52]\]                      Germany                             1964-75   97     3.00   Yes   No    Yes   No    At diagnosis   No
  Latour 1996 \[[@B45]\]                       Belgium                             1993-94   56     5.50   Yes   Yes   Yes   No    At diagnosis   No

###### 

Characteristics of case--control studies for ulcerative colitis and Crohn's disease studies

  **Study characteristics and demographics**   **Study quality characteristics**                                                                                                                                                                                  
  -------------------------------------------- ----------------------------------- ----- -------- -------------------------------------------------- ------------------------------------------------ ----- ----- ----- ---- ------------------------------------ -----
  *Ulcerative Colitis*                                                                                                                                                                                                                                            
  Parrello 1997 \[[@B26]\]                     Italy                               509   657      Attending orthopedic and surgical clinics          Sex, age, year of diagnosis                      Yes   Yes   No    No   Time of data collection              No
  Feeney 2002 \[[@B17]\]                       UK                                  137   137      Functional GI Disorders                            Sex, age                                         Yes   Yes   No    No   Childhood (age 0--5)                 No
  Bernstein 2007 \[[@B27]\]                    Canada                              137   310      Manitoba Health Population Registry                Sex, age                                         No    N/A   No    No   N/A                                  No
  Jiang 2007 \[[@B28]\]                        China                               177   177      Neighbours or colleagues                           Sex, age                                         Yes   Yes   No    No   Childhood                            No
  Radon 2007 \[[@B54]\]                        Germany                             304   1481     Strabismus surgery                                 Age                                              No    N/A   No    No   Time of data collection              No
  Martinez Salmeron 1994 \[[@B46]\]            Spain                               63    63       Hospital                                           Sex, age                                         Yes   Yes   Yes   No   Time of data collection              No
  Ekbom 1990 \[[@B8]\]                         Sweden                              164   328      Live births between 1924--1957 in Uppsala County   Date of birth, sex, and maternal age or parity   Yes   Yes   Yes   No   Time of birth                        No
  *Crohn's Disease*                                                                                                                                                                                                                                               
  Feeney 2002 \[[@B17]\]                       UK                                  139   139      Functional GI disorders                            Sex, age                                         Yes   Yes   No    No   Childhood (age 0--5)                 No
  Bernstein 2007 \[[@B27]\]                    Canada                              235   310      Manitoba Health Population Registry                Sex, age                                         No    N/A   No    No   N/A                                  No
  Ponsonby 2009 \[[@B53]\]                     Australia                           278   998321   Live births from 1983--1998 in Victoria            Age                                              Yes   No    Yes   No   Childhood (age 0--6)                 No
  Malekzadeh 2009 \[[@B16]\]                   Iran                                196   207      IBS treated by an expert gastroenterologist        Age                                              Yes   Yes   No    No   Childhood (before 16^th^ birthday)   No
  Radon 2007 \[[@B54]\]                        Germany                             444   1481     Strabismus surgery                                 Age                                              No    N/A   No    No   Time of data collection              No
  Thompson 1998 \[[@B29]\]                     England, Wales                      291   1682     Same GP                                            Sex, age                                         No    N/A   No    No   N/A                                  No
  Wurzelmann 1994 \[[@B13]\]                   United States                       322   262      Closest neighbour                                  Sex, age, race                                   No    N/A   No    No   Childhood (age 0--5)                 Yes
  Martinez Salmeron 1994 \[[@B46]\]            Spain                               30    30       Hospital                                           Sex, age                                         Yes   Yes   Yes   No   Time of data collection              No
  Ekbom 1990 \[[@B8]\]                         Sweden                              93    186      Live births between 1924--1957 in Uppsala County   Date of birth, sex, and maternal age or parity   Yes   Yes   Yes   No   Time of birth                        No

Urban/rural environment and IBD
-------------------------------

The pooled crude IRR for the 25 UC studies was 1.17 (1.03, 1.32) (Figure [2](#F2){ref-type="fig"}A). For the 18 cohort studies, the pooled crude IRR was 1.19 (1.03, 1.36) (Figure [2](#F2){ref-type="fig"}B). In 13 of the studies, a positive association between UC and urban environment was found, 7 of which were statistically significant. Heterogeneity across studies was observed (Q statistic, 95.14; *P* \< .001). For the UC case--control studies, the pooled OR for the association between urban environment and UC was 1.06 (0.78, 1.45) (Figure [2](#F2){ref-type="fig"}C). Three out of seven studies found a positive association, and two were statistically significant. Heterogeneity was observed across studies (Q statistic, 19.32; *P* = .004). The pooled IRR for the 30 CD studies was 1.42 (1.26, 1.60) (Figure [3](#F3){ref-type="fig"}A). For the 21 cohort studies, the pooled crude IRR was 1.50 (1.30, 1.72) (Figure [3](#F3){ref-type="fig"}B). In 20 of the studies, a positive association between CD and urban environment was found, 10 of which were statistically significant. Heterogeneity across cohort studies was observed (Q statistic, 108.56; *P* \< .001). For the 9 CD case--control studies, the pooled OR for the association between urban environment and CD was 1.26 (1.03, 1.53) (Figure [3](#F3){ref-type="fig"}C). Six out of the seven studies found a positive association, but only three were statistically significant. Heterogeneity was not observed across studies (Q statistic, 11.88; *P* = .157).
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![Forest plot of the summary effect estimate with 95% CI studies that explored the relationship between urban environment and Crohn's disease for both cohort and case--control studies (A); cohort studies (B); and case--control studies (C).](1471-230X-12-51-3){#F3}

Sensitivity and stratified analyses
-----------------------------------

After excluding the UC cohort studies that did not define urban and/or rural environment the pooled IRR was 1.18 (1.09, 1.27), which did not differ from the crude pooled IRR (Table [3](#T3){ref-type="table"}). The IRR lost significance 1.16 (0.9, 1.5) when we included only studies that defined urban as \>10,000 people. Only cohort studies published after 1999 demonstrated an association between urban environment and UC (1.30; 95% CI: 1.10, 1.54). A stratified analysis was similarly performed for region in which the study was based, divided into European and non-European countries. The IRR for Non-European studies was statistically significant with pooled estimate of 1.13 (1.06, 1.22). Meta-regression was not statistically significant for year of publication, region of publication and European countries.

###### 

Sensitivity and stratified analyses of pooled relative risk for cohort studies

                                              **Ulcerative colitis**   **Crohn's disease**                                                                                               
  ------------------------------------------- ------------------------ --------------------- ------------------ -------- ------- ------ ---- ------ ------------------ -------- -------- -----
  Crude                                       18                       6901                  1.19(1.03, 1.36)   \<.001                  21   6514   1.50(1.30, 1.72)   \<.001             
  **Definition of urban/rural environment**                                                                                                                                              
  Urban/rural defined                         13                       5906                  1.18(1.09, 1.27)   .19                     16   5741   1.28(1.14, 1.43)   \<.001             
  Urban defined as \>10,000                   3                        299                   1.16(0.90, 1.50)   .65                     4    488    1.38(0.97, 1.97)   .072               
  **Year of publication**                                                                                                                                                                
  1962-1988                                   3                        860                   0.96(0.60, 1.51)   \<.001   0.16    .30    6    825    1.90(1.27, 2.85)   \<.001   −0.095   .47
  1989-1998                                   9                        3459                  1.23(0.95, 1.57)   \<.001                  9    3176   1.26(1.04, 1.53)   \<.001             
  1999-2009                                   6                        2612                  1.30(1.10, 1.54)   .022                    6    2513   1.49(1.18, 1.87)   .001               
  **Region**                                                                                                                                                                             
  European countries                          15                       5036                  1.21(0.99, 1.46)   \<.001   0.008   .98    17   4295   1.55(1.28, 1.88)   \<.001   0.77     .75
  Non-European countries                      3                        1895                  1.13(1.06, 1.22)   .61                     4    2219   1.39(1.18 1.62)    .12                
  **European Countries**                                                                                                                                                                 
  Northern                                    6                        3819                  0.97(0.75, 1.27)   \<.001   −0.26   .086   9    3499   1.23(1.04, 1.45)   \<.001   0.23     .04
  Eastern                                     2                        723                   1.59(0.98, 2.59)   .013                    2    297    2.30(0.54, 9.82)   \<.001             
  Mediterranean                               6                        458                   1.39(0.82, 2.36)   \<.001                  4    346    2.64(1.50, 4.62)   .02                
  Western                                     1                        36                    2.12(1.00, 4.50)   NA                      2    153    1.72(1.17, 2.51)   .79                

For the UC case--control studies, we failed to find a statistically significant association when stratifying by timing of exposure (Table [4](#T4){ref-type="table"}). Meta-regression was performed for both timing of exposure and source of controls and no statistically significant associations were found.

###### 

Sensitivity and stratified analyses of pooled odds ratio for case--control studies

                            **Ulcerative colitis**   **Crohn's disease**                                                                                                           
  ------------------------- ------------------------ --------------------- ------ ------------------- ------ ------- ----- --- ------ --------- ------------------- ------ ------- -----
  Crude                     7                        1491                  3153   1.06 (0.78, 1.45)   .004                 9   2028   1002618   1.26 (1.03, 1.53)   .16             
  **Time of exposure**                                                                                                                                                             
  Time of data collection   4                        1013                  2511   1.18 (0.78, 1.80)   .006   -0.32   .42   2   474    1511      1.21 (0.58, 2.50)   .18    0.060   .89
  Childhood                 3                        478                   642    0.87 (0.65, 1.17)   .91                  5   1028   999115    1.18 (0.82, 1.70)   .052            
  0-6 years                                                                                                                4   832    998908    1.12 (0.71, 1.77)   .026   0.16    .46
  \< 16 years                                                                                                              1   196    207       1.39 (0.74, 2.60)   NA              
  **Source of controls**                                                                                                                                                           
  Population                2                        314                   487    1.02 (0.66, 1.58)   .16    0.035   .94   3   835    998893    1.40 (1.13, 1.73)   .37    -0.23   .32
  Clinic/Hospital           5                        1177                  2666   1.06 (0.70, 1.60)   .003                 6   1193   3725      1.09 (0.79, 1.51)   .11             

After excluding CD cohort studies that did not define urban and/or rural environment, the pooled IRR was 1.28 (1.14, 1.43), which was similar to the crude IRR (Table [3](#T3){ref-type="table"}). Restricting the urban definition to \>10,000 people resulted in a loss of significance with an IRR of 1.38 (0.97, 1.97). The pooled IRRs were statistically significant across all 3 categories of publication year (Table [3](#T3){ref-type="table"}). A stratified analysis was similarly performed for region in which the study was based, divided into European and non-European countries. The IRRs for both European and non-European studies were statistically significant with pooled estimates of 1.55 (1.28, 1.88) and 1.39 (1.18, 1.62), respectively. In meta-regression analysis only the European countries variable was statistically significant (Table [3](#T3){ref-type="table"}).

For the CD case--control studies, we failed to find a statistically significant association when stratified by timing of exposure (Table [4](#T4){ref-type="table"}). Meta-regression was performed for both time of exposure and source of controls and no statistically significant associations were found. The OR for population-based controls was 1.40 (1.13, 1.73) and for hospital/clinic-based controls was 1.09 (0.79, 1.51). Meta-regression was performed for both variables and no statistically significant result was found.

Publication bias
----------------

No publication bias was found; the Begg tests were not statistically significant for UC (z = −0.42, *P* = .675) or CD studies (z = 0.70, *P* = .487).

Discussion
==========

Urbanization of society is an important risk factor for the development of IBD. This meta-analysis suggests that living in urban environments may increase the risk of developing CD and UC. Though, the strengths of association varied among the 40 studies due to heterogeneity between studies. The association between CD and urban environment persisted across a number of stratified analyses that explored clinical and study quality factors. In contrast, the association between UC and urban environment was weaker and less consistent upon sensitivity analyses. Publication bias was not observed suggesting that the association were likely not an artifact of unpublished studies.

Several theories may explain the increased incidence of IBD in urban societies. The Hygiene Hypothesis proposes that the lack of early childhood exposure to enteric pathogens with improved sanitation in urban cities increases the incidence of IBD \[[@B5],[@B55]\]. The lack of exposure to enteric pathogens may lead to a greater susceptibility to develop an inappropriate immunologic response upon exposure to new antigens (e.g. gastrointestinal infection) later in life \[[@B56]\]. Other environmental risk factors of IBD that are more predominant in urban societies include smoking, lack of helminths exposure, and antibiotic use \[[@B57]-[@B59]\]. Additionally, a recent study demonstrated that air pollution in urban cities was associated with IBD in children \[[@B60]\]. Urban occupations such as driving and manufacturing have also been reported as risk factors for IBD \[[@B61]\]. While a cohesive hypothesis that explains the environmental determinants of IBD has not been proven, this meta-analysis supports further research exploring the environmental risk factors of urbanization and IBD.

Heterogeneity was observed in both the CD and UC cohort studies, whereas statistically significant heterogeneity was not observed for the UC and CD case--control studies. This inconsistency was likely due to the large overall study population in the cohort studies, leading to an overpowered heterogeneity statistical test. In contrast, the case--control studies were small in total study population. Alternatively, differences in heterogeneity between studies may be explained by the difference in the study design and by the intrinsic biases associated with cohort and case--control studies that explore environmental risk factors of IBD.

When studies were stratified by region the association between UC and urban environment persisted only in non-European studies, whereas the association between CD and urban environment remained significant in most regions. Regional differences may be due to the fact that studies originated from countries that differed by ethnicity, prevalence of IBD, and rates of IBD susceptibility genes \[[@B62],[@B63]\]. Alternatively, the small number of studies in each region made appropriate and meaningful inferences challenging. Furthermore, data was lacking for low prevalent regions (i.e. developing world) and thus we could not explore the urban/rural effect in these regions.

We explored whether the year of publication contributed to the heterogeneity observed between studies. For UC, only publications after 1999 were significant after pooling. This time stratified finding may be due to study design differences in more recent publications or the changing pattern of UC diagnosis. In contrast, the urban/rural relationship persisted across all time strata for CD, which suggested a greater strength of association for CD over UC.

The definition of an urban environment was a source of heterogeneity across studies. The studies that clearly defined this exposure included population estimates of the urban and/or rural areas; however, the inconsistency or lack of definitions made study comparisons challenging. We a priori selected the definition of urban as more than 10,000 people because this definition is consistent with census of populations in many Countries (e.g. United Kingdom \[[@B37]\] and Canada \[[@B38]\]). When considering only studies that defined urban as \>10,000, the association was no longer significant, which was likely due to the small number of studies with this definition (n = 2 for UC and n = 4 for CD). However, this finding may also reflect that the risk associated with urban society may be driven by greater population size (e.g. living in a metropolis) and/or by population density. Ideally, we would have investigated the potential for a dose response effect to explore whether the risk of IBD increased with increasing population sizes. However, few papers stratified their results by multiple levels of exposure; for example, Tsianos \[[@B24]\] and Ladas \[[@B34]\] stratified their analysis into urban, semi-rural, and rural. Future studies of the urban--rural association should explore the importance of a dose response effect, a threshold value of population size, and population density.

Heterogeneity between studies may have occurred due to the biases associated with cohort and case--control studies. For the case--control studies, a selection bias may have influenced the association if cases were selected by a different mechanism than controls. The controls were grouped into population- and hospital/clinic-based selection categories. For CD, only population-based controls demonstrated a significant association with urban environment; in contrast, the urban--rural association was insignificant in both control populations for UC. Additionally, inconsistency in timing of exposure (e.g. defining urban--rural status at time of diagnosis versus childhood) may have contributed to the heterogeneity between case--control studies. People in rural settings may have less access to health care leading to under diagnosis of IBD. Although the majority of the case--control studies were matched by age and gender, other potential confounders including socioeconomic status and smoking were often not considered. Finally, studies that used administrative databases to identify IBD patients likely introduced misclassification errors. Interpreting the results of meta-analysis should be cautious because pooling data does not address the intrinsic biases of observational studies.

Limitations in our systematic review should be considered. First, the number of studies included in the stratified analyses was small and may have been underpowered. Second, the quality of studies was not always optimal as was shown with the inconsistent definitions of urban/rural and time of exposure. Third, the included studies used population estimates as indicators for urban environment; however, other factors that contribute to an urban setting, such as socioeconomic characteristics, were not considered. Finally, due to the nature of observational studies, a temporal relationship could not be determined. Thus, urban environment cannot be conclusively established as a causal factor in IBD.

Conclusions
===========

In spite of differences in study design and population characteristics, the meta-analysis demonstrated that living in an urban society was positively associated with the development of IBD; though, the consistency and strength of the association was greatest for CD. Additionally, the meta-analysis identified important study limitations and thus, future studies should be properly designed using a standard definition of urban/rural. Furthermore, additional studies are need to evaluate whether the following factors affect the risk of developing IBD: increasing population size (i.e. a dose response effect); a threshold value of population size; the number of people living per unit area (i.e. population density); and the duration and timing of exposure. Finally, the meta-analysis highlights that researchers should continue to explore for environmental differences between urban and rural societies.
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